Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
PMMA Platform Based Micro Fluidic Mixer for the Detection of MicroRNA- 18a from Retinoblastoma Serum
Bindu Salim1*, Swapna Merlin David1, Madhu Beta2, Janakiraman Narayanan2, Subramanian Krishnakumar2 and Thalakkotur Lazar Mathew1
1PSG Institute of Advanced Studies, Coimbatore, Tamil Nadu, India
2Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India
- *Corresponding Author:
- Bindu Salim
PSG Institute of Advanced Studies
Coimbatore, Tamil Nadu, India
Tel: +91-9790039955
Fax: +91-422-2573833
E-mail: bbs@psgias.ac.in
Received date: June 12, 2015; Accepted date: July 20, 2015; Published date: July 27, 2015
Citation: Salim B, Merlin David S, Beta M, Narayanan J, Krishnakumar S, et al. (2015) PMMA Platform Based Micro Fluidic Mixer for the Detection of MicroRNA-18a from Retinoblastoma Serum. J Anal Bioanal Tech 6:258. doi: 10.4172/2155-9872.1000258
Copyright: © 2015 Salim B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Retinoblastoma (RB) is an eye cancer found in children. Early diagnosis of RB is very crucial for the treatment to be effective. miRNA 18a is highly expressed in the serum of RB patients which can be used as a diagnostic marker to detect RB. A pillar based micro mixer is designed and fabricated on PMMA platform to hybridize the target miRNA 18a with its complementary quenched probe throughout the flow. The fluorescence can be measured in the monitoring well by the fluorescent reader at a particular wavelength and compared with the controls. The RB serums showed high fluorescence than the controls. The results were validated with the contemporary technique, Real-Time PCR and the results were concurring. Another advantage of the device is that the effort required for the immobilization of the probe on a platform is not needed, at the same time cost and time required for diagnosis is reduced.
